Stumbled upon this one when I did my research last night. This company, Motion DNA (Symbol: MTDX) was founded to commercialize its innovative, diagnostic motion capture system that monitors and identifies physical characteristics for improvement of the motions of the human body. The company markets this technology to medical professionals, sports organizations, professional athletes, and even large companies looking to prevent physical strain and injury to its employees. They provide analyses and detailed reports to its licensees and consumers with solutions for preventing injuries, identifying physical limitations, diagnosing pre-existing injuries related to biomechanics, and improving physical performance levels.

Looking at their historical data, I’m little bit sceptical if this stock is going to perform well in the future. A month ago, they were traded at 0.18/share; 3 months ago they were traded as high as $0.30/share. Hell a year ago, they were traded at $1/share. Currently they’re traded at $0.01/share. There must be a good reason why the price dropped a lot within one year.

Recently there was an article about them published in Business Wire. Here it is:

“Motion DNA Corporation (OTC:MTDX) officials announced today an upcoming marketing schedule of events for 2004 and 2005. The marketing schedule kicks off with demonstrating its products and services at the upcoming Baseball Tradeshow in Anaheim, California, December 10-12, 2004. Company officials expect to expose the company’s technology to professional baseball teams of all levels at the convention. Coaches, front office executives, and medical professionals representing teams from the MLB and minor league organizations are expected to attend the tradeshow, which is held in conjunction with the Baseball Winter Meetings for professional teams. Representatives in baseball from collegiate and professional teams have expressed an increasing interest in Motion DNA’s analysis primarily for evaluating the risks of shoulder and elbow injuries in pitchers. An injury to a key player can cost a professional team millions of dollars each year. The losses add up when teams look at wages paid to the injured player, lost gate receipts, and missed post season revenues due to the injury to one player.
“Our goal is annual testing for athletes involved in sports where there is a high risk of injury to a particular group. The fee for Motion DNA’s full analysis for a pitcher ranges from $200 to $900 per player depending upon our report’s detail and could add up to over $200,000 per team,” said Zig Ziegler, President of Motion DNA.
“However, the company offers a much lower flat fee for annual contracts with a schedule consisting of 4 tests annually for pitchers only conducted at a site determined by the client.”
Company officials believe that if major league baseball requires its at-risk athletes to be tested, collegiate and high school programs are sure to follow suit, along with other sports.
“If I am the owner of a professional team spending millions of dollars on even one player … counting on them to stay healthy, this is just a small fee to help ease my mind and insure my product (which in today’s sports business world is the athlete) works properly,” added Ziegler. (http://biz.yahoo.com/bw/041128/285028_1.html November 28, 9:40 am - Yahoo Finance)

So what do you think, huh? At $0.01/share, this stock might not be a bad investment. It’s cheap, judging from the services offered - looks like they still have a good potential to become a bigger company, and it’s a low risk. Put in a hundred bucks, you’ll get 1,000 shares. When the price hits 50 cents or something, you’ll cash out $500…Not bad, huh?

Quote of the Day:
Wealth consists not in having great possessions, but in having few wants. - Epicurus